Mirabegron Use for OAB Rising, Anticholinergic Use Falling
Mirabegron use for overactive bladder rose to 16% in 2016, whereas anticholinergic use decreased to 78% in 2016 from 97% in 2003, a study found.
PHILADELPHIA—Mirabegron use is on the rise and anticholinergic use is decreasing as treatments for overactive bladder (OAB), according to data presented at the International Continence Society's 2018 annual meeting.
Using a national administrative health and pharmacy claims database, Raveen Syan, MD, and collaborators at Stanford University School of Medicine in Palo Alto, California, examined OAB management trends from 2003 to 2016 in a cohort of 3,519,529 patients diagnosed with non-neurogenic OAB. Of these, 18% received medical treatment, with 17% prescribed oral therapy only and 0.7% prescribed advanced therapies (bladder chemodenervation, sacral neurmodulation, and peripheral tibia nerve stimulation [PTNS]).
Use of mirabegron, which received FDA approval in 2012, increased to 16% in 2016, whereas anticholinergic use declined from 97% in 2003 to 78% in 2016. Use of bladder chemodenervation rose from 2% in 2003 to 4% in 2016. Sacral neuromodulation and PTNS remained low at 0.4% and 0.01% in 2016.
That the rise in migabegron use coincided with declining anticholinergic use suggests physicians are increasing using mirabegron, the authors concluded.
The study population, which had a mean age of 57 years, was 61% female and 73% white.
Syan R, Zhang CA, Dallas K, Enemchukwu E. Trends in the management of overactive bladder in the United States from 2003–2016. Data presented at the International Continence Society's 2018 annual meeting in Philadelphia, August 28–31.